Weight Gain in Persons with HIV Switched from Efavirenz-based to Integrase Strand Transfer Inhibitor-based Regimens.

Norwood J, Turner M, Bofill C, Rebeiro P, Shepherd B, Bebawy S, Hulgan T, Raffanti S, Haas DW, Sterling TR, Koethe JR. Weight Gain in Persons with HIV Switched from Efavirenz-based to Integrase Strand Transfer Inhibitor-based Regimens. Journal of acquired immune deficiency syndromes (1999). 2017 Aug 18. PMID: 28825943 [PubMed]

With the introduction of integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART), persons living with HIV have a potent new treatment option. Recently, providers at our large treatment clinic noted weight gain in several patients switched from efavirenz/tenofovir disoproxil fumarate/emtricitabine (EFV/TDF/FTC) to dolutegravir/abacavir/lamivudine (DTG/ABC/3TC). In this study, we evaluated weight change in patients with sustained virologic suppression switched from EFV/TDF/FTC to an INSTI-containing regimen.